List of Excipients in Branded Drug POLYETHYLENE GLYCOL 3350, NF POWDER FOR SOLUTION, LAXATIVE

Generic Drugs Containing POLYETHYLENE GLYCOL 3350, NF POWDER FOR SOLUTION, LAXATIVE

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	polyethylene glycol 3350, nf powder for solution, laxative	21695-598	AIR

What are the Most Frequently-Used Excipients in POLYETHYLENE GLYCOL 3350, NF POWDER FOR SOLUTION, LAXATIVE?

# Of NDCs	Excipient
1	AIR

Polyethylene Glycol 3350 NF Powder for Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 4, 2026

Polyethylene glycol 3350, NF, is an osmotic laxative active ingredient rather than an excipient. The primary commercial opportunities are differentiated oral powders, flavored and low-sugar presentations, unit-dose packaging, pediatric-friendly formats, and combination products that improve adherence without changing the established 17-gram daily-use profile. The core PEG 3350 powder market has low formulation complexity, limited patent barriers, and substantial price competition.

What is the regulatory status of polyethylene glycol 3350 powder for solution?

PEG 3350 is marketed in the United States as an over-the-counter osmotic laxative. The product is supplied as a white, water-soluble powder that is dissolved in 4 to 8 ounces of liquid before oral administration. The typical labeled dose is 17 grams once daily, with use generally limited to seven days unless directed by a health professional [1, 2].

The regulatory framework is based primarily on the FDA laxative monograph rather than a product-specific innovation pathway. FDA OTC monograph M007 identifies osmotic laxative ingredients and establishes labeling and use conditions for eligible products [1].

Item	Commercial position
Active ingredient	Polyethylene glycol 3350
Compendial grade	PEG 3350, NF
Drug category	Osmotic laxative
Dosage form	Powder for oral solution
Typical adult dose	17 g once daily
Administration	Dissolve in 4-8 ounces of beverage
Primary FDA pathway	OTC monograph
Prescription status	Also used in prescription bowel-preparation and electrolyte products, which are separate formulations
Main brand	MiraLAX
Generic competition	Extensive, including private-label and store-brand products

PEG 3350 should not be confused with PEG-electrolyte lavage solutions. Products such as GoLYTELY and equivalent bowel-preparation products contain PEG 3350 with electrolytes and have different formulations, indications, dosing regimens and labeling [3].

Which excipients are used in PEG 3350 powder products?

The simplest PEG 3350 laxative contains PEG 3350 as the only functional ingredient. This creates a narrow excipient strategy. Added materials must improve handling, palatability, stability or packaging without compromising dissolution or the product's unflavored positioning.

Core excipient functions

Formulation objective	Suitable excipient or material strategy	Commercial purpose
Improve taste	Sucralose, acesulfame potassium, sugar, polyols or flavor systems	Supports flavored and pediatric-oriented products
Improve mouthfeel	Maltodextrin, mannitol or compatible bulking agents	Reduces perceived powderiness
Improve flow	Colloidal silicon dioxide or equivalent glidant	Supports high-speed filling and sachet manufacture
Prevent caking	Moisture-barrier packaging and controlled humidity processing	Preserves powder handling and dose uniformity
Add flavor	Citrus, berry, orange, lemon-lime or neutral flavor systems	Creates brand differentiation
Improve unit-dose performance	Co-processed carrier or engineered granulation	Supports stick packs and portable doses

Many marketed PEG 3350 products use no added excipients or use limited flavoring and sweetening systems. DailyMed listings show that formulations vary materially by manufacturer and product presentation [2].

Why minimal-excipient formulations remain attractive

A minimal formula provides several advantages:

• Lower raw-material cost.
• Simpler regulatory and quality documentation.
• Lower risk of incompatibility.
• Easier dose uniformity control.
• Fewer allergen and dietary claims.
• Better alignment with consumers seeking a tasteless product.

The main technical drawback is limited product differentiation. A product that is chemically equivalent to existing generic PEG 3350 powders competes primarily on price, package count, retailer placement and consumer trust.

What formulation patents protect PEG 3350 laxative products?

The base PEG 3350 powder formulation has limited patent differentiation because the active ingredient, dosage concept and administration method are mature. Commercial protection is more likely to arise from packaging, flavor systems, manufacturing processes, delivery formats or combination products than from PEG 3350 itself.

Patent categories with potential value

Patent category	Potential scope	Commercial strength
PEG 3350 composition	Defined molecular-weight distribution or purity profile	Low to moderate
Flavor system	Specific masking agents, flavor ratios or sensory profile	Moderate if difficult to design around
Powder processing	Granulation, particle engineering, flow or dissolution	Moderate
Unit-dose packaging	Moisture protection, dose delivery or child-resistant design	Moderate
Pediatric formulation	Age-specific dosing, taste masking or dispersibility	Moderate
Combination product	PEG 3350 with fiber, probiotic or another laxative	Variable and potentially stronger
Digital adherence system	Dose tracking, reminders or connected packaging	Usually utility-patent dependent
Manufacturing process	Defined drying, blending or milling conditions	Moderate if process produces a measurable advantage

The strongest practical protection is often regulatory execution, supply reliability and retail distribution rather than composition-of-matter patent protection. A formulation patent must provide a measurable technical benefit, such as improved dissolution, reduced caking, better taste acceptance or superior stability.

When does PEG 3350 lose exclusivity?

PEG 3350 does not have a commercially meaningful modern exclusivity period comparable to a newly approved prescription drug. The active ingredient has long been available, and OTC monograph products can enter without relying on a conventional new-drug exclusivity period when they comply with applicable FDA requirements.

MiraLAX was approved as an OTC laxative product before the current monograph framework matured. Its commercial position is protected primarily by brand recognition, retail distribution and consumer familiarity rather than by a current blocking patent estate. Generic and private-label PEG 3350 products are widely marketed.

Exclusivity type	PEG 3350 powder status
New chemical entity exclusivity	Not applicable
Orphan exclusivity	Not applicable
Pediatric exclusivity	No material current barrier identified
OTC monograph exclusivity	No product-specific market monopoly
Composition patent protection	Mature technology; no broad current barrier apparent from cited regulatory records
Brand protection	Trademark, packaging and consumer recognition
Retail protection	Distribution agreements and shelf placement

Exact patent expiration analysis requires a claim-level review of U.S. and foreign patent records. The commercial conclusion is clearer: the standard PEG 3350 powder category is open to generic entry and already contains extensive competition.

What is the Orange Book status of PEG 3350 laxative products?

The Orange Book is not the principal source of market protection for OTC monograph PEG 3350 powders. Orange Book-listed prescription products and approved NDAs can have patent and exclusivity listings, but an OTC monograph product does not receive the same type of patent-based market control as a patented prescription medicine [4].

The distinction is important for launch planning:

• An OTC monograph product generally does not require a Paragraph IV certification to enter the market.
• A generic applicant relying on an approved prescription NDA would face a different pathway.
• Prescription PEG-electrolyte bowel-preparation products should be analyzed separately.
• Brand-name trademarks and trade dress remain enforceable even when the active ingredient is freely available.

A standard OTC PEG 3350 powder launch therefore tends to be a formulation, labeling, manufacturing and distribution project rather than an Abbreviated New Drug Application strategy.

What generic entry risks exist for PEG 3350 powder?

Generic entry risk is high because the product has low technical complexity and numerous contract manufacturers can produce comparable powders. Price erosion is the central risk for an undifferentiated launch.

Main competitive risks

1. Private-label substitution. Retailers can source store-brand PEG 3350 products at lower prices.
2. Low switching costs. Consumers can move between brand and generic powders with little clinical disruption.
3. Retailer bargaining power. Large pharmacy, grocery and mass-market chains can compress wholesale margins.
4. Commodity supply. PEG 3350 is available from multiple chemical and pharmaceutical suppliers.
5. Limited clinical differentiation. Standard products have the same active ingredient and similar dosing instructions.
6. Packaging duplication. Competitors can use comparable jars, sachets and stick packs without copying protected trade dress.

A differentiated product should avoid competing solely on the 17-gram powder itself. The commercial proposition should target convenience, taste, portability, sustainability, adherence or a defined consumer segment.

What excipient strategies create commercial opportunities?

1. Flavored, low-sugar powder

A flavored product can target consumers who dislike the neutral taste or texture of unflavored PEG 3350. Citrus, berry and lemon-lime systems are commercially intuitive. A low-sugar formulation can address consumers managing caloric intake, while a sugar-free product can broaden use among diabetic consumers, subject to appropriate labeling and excipient tolerance.

Key development requirements include:

• Rapid dissolution without visible sediment.
• Stable flavor over shelf life.
• No excessive sweetness after dilution.
• Compatibility with water, juice and other permitted beverages.
• No color change or odor development.
• Clear distinction from unflavored branded products.

2. Single-use stick packs

Stick packs reduce measuring errors and improve portability. They can support travel, workplace and on-the-go use. A 17-gram unit dose is straightforward from a fill-weight perspective, but powder flow, electrostatic charge and moisture ingress become critical manufacturing variables.

The principal protection opportunity is not the stick-pack concept alone. A stronger position would combine:

• A moisture-resistant laminate.
• Improved powder flow.
• Consistent fill weight.
• Easy-tear opening.
• Compact carton architecture.
• Child-resistant secondary packaging where required.

3. Pediatric-oriented presentation

PEG 3350 is widely used in pediatric practice, but pediatric commercialization requires careful attention to labeling, dose flexibility and palatability. A fixed 17-gram dose is not inherently optimized for children. A product can target caregivers through graduated dosing tools, smaller unit doses or a flavor system that disperses in common beverages.

The commercial and regulatory risk is that pediatric claims may require evidence and labeling review beyond a simple adult OTC presentation. A company should not assume that a child-friendly format permits pediatric claims without supporting regulatory analysis.

4. Sustainable packaging

Packaging reduction is a credible retail differentiator. Opportunities include:

• Recyclable jars.
• Reduced-plastic refill pouches.
• Paperboard cartons with barrier liners.
• Smaller secondary cartons.
• Concentrated unit-dose packaging.

The technical challenge is moisture control. PEG 3350 powders can cake or lose handling performance when exposed to humidity. Any sustainability initiative must preserve container-closure integrity and shelf-life specifications.

5. Combination products

Combining PEG 3350 with fiber, probiotics, electrolytes or another laxative could create a differentiated platform. These products also carry the highest regulatory and clinical risk.

PEG 3350 plus electrolytes moves the product toward bowel preparation or medically supervised rehydration. Fiber combinations can create tolerability, bloating and dosing issues. Probiotic combinations raise stability and strain-specific substantiation questions. A combination product should be treated as a new formulation program, not as a simple line extension.

How strong is the PEG 3350 patent estate?

The standard PEG 3350 powder estate is commercially weak as a blocking platform and stronger as a field for narrow improvement patents.

Estate component	Assessment
Active ingredient	Mature and broadly available
Standard 17-gram powder	Low differentiation
Basic oral solution use	Low patent leverage
Flavor masking	Moderate opportunity
Moisture-control packaging	Moderate opportunity
Pediatric delivery	Moderate, subject to claim support
Manufacturing process	Moderate if tied to measurable performance
Combination formulations	Potentially stronger but higher regulatory burden
Brand and trade dress	Practical commercial value
Supply-chain qualification	High operational value, not patent exclusivity

A freedom-to-operate review should focus on active claims covering specific excipient ratios, particle-size distributions, packaging structures, manufacturing steps and combination uses. Broad claims directed only to PEG 3350 as an osmotic laxative are unlikely to provide a durable competitive moat.

Which companies are competing in PEG 3350 laxatives?

The competitive field includes Bayer's MiraLAX brand, national pharmacy and grocery private labels, generic pharmaceutical companies, and contract manufacturers supplying retailer-branded products. Competitive success depends on channel access more than clinical differentiation.

Competitive dimensions

Dimension	Brand leader	Generic/private label	New entrant
Consumer awareness	High	Variable	Low initially
Price	Premium	Low	Must be competitive
Formulation flexibility	Moderate	Moderate	High
Retail access	Established	Strong through retailer ownership	Requires contracting
Patent leverage	Limited	Limited	Potentially narrow
Packaging innovation	Moderate	Variable	Main opportunity
Margin potential	Higher at brand level	Lower per unit	Depends on differentiation

A new entrant can pursue one of three strategies: private-label supply, branded differentiated OTC product, or a specialty formulation platform. Private-label supply offers volume but thin margins. A branded product offers greater margin potential but requires advertising and distribution investment. A specialty platform offers the greatest defensibility but also carries the highest regulatory cost.

What manufacturing and intellectual-property barriers affect launch?

The main barriers are operational rather than legal.

Manufacturers must control:

• PEG 3350 identity and compendial compliance.
• Molecular-weight distribution.
• Particle size and powder flow.
• Moisture content.
• Blend uniformity.
• Fill-weight accuracy.
• Dissolution and dispersion.
• Container-closure integrity.
• Microbial and foreign-material controls.
• Stability under temperature and humidity stress.

A reliable supply chain requires qualified PEG 3350 suppliers, dual-source planning and validated packaging. Packaging is particularly important because a low-cost powder can become commercially unusable if it cakes, bridges in the filling line or fails to dissolve uniformly.

What FDA regulatory strategy is most practical?

For a standard PEG 3350 powder that complies with the OTC laxative monograph, the lowest-risk pathway is an OTC monograph product with conservative labeling and a formulation close to established market products [1].

A company pursuing added flavor, sweetener or packaging innovation should maintain the core monograph-compliant use and avoid unsupported therapeutic claims. The regulatory burden increases when the product:

• Changes the active dose.
• Adds another active ingredient.
• Makes pediatric claims outside established labeling.
• Uses a novel delivery system.
• Claims superior efficacy or faster onset.
• Combines PEG 3350 with electrolytes or other active ingredients.

The label should clearly distinguish PEG 3350 laxative powder from bowel-preparation products. Confusion between daily laxative use and colonoscopy preparation creates avoidable safety and compliance risk.

What is the revenue exposure and commercial outlook?

PEG 3350 products participate in a large, mature constipation market, but individual product economics depend on channel and price. A standard bottle has limited differentiation and is exposed to rapid private-label substitution. Revenue durability improves with recurring-use behavior, strong retailer placement, and differentiated packaging.

The strongest commercial opportunities are:

1. Retailer-exclusive private-label manufacturing.
2. Unit-dose travel packs.
3. Low-sugar flavored formulations.
4. Pediatric-oriented dosing formats.
5. Refill and sustainable packaging.
6. International OTC registrations using a common technical dossier.
7. Contract manufacturing for pharmacy and grocery chains.
8. Premium products with verified dissolution and palatability advantages.

The weakest opportunity is another unflavored jar with the same dose, package count and claims as existing store brands.

Key Takeaways

• PEG 3350 is the active laxative ingredient, not an excipient.
• Standard PEG 3350 powder products have low formulation complexity and high generic-entry risk.
• The OTC monograph is more important than Orange Book exclusivity for ordinary laxative powders.
• The base product has limited blocking-patent potential.
• Formulation patents are more viable for taste masking, moisture control, pediatric dosing and manufacturing performance.
• Unit-dose packaging, flavored low-sugar products and sustainable containers offer the clearest commercial differentiation.
• PEG-electrolyte bowel-preparation products require separate regulatory, clinical and patent analysis.
• Supply reliability, packaging performance and retail access are more important than broad patent exclusivity.
• A new product should compete on convenience or adherence rather than on the 17-gram PEG 3350 dose alone.

FAQs

Is polyethylene glycol 3350 an excipient or an active ingredient?

PEG 3350 is an active osmotic laxative ingredient in products labeled for constipation relief. It can also appear as a formulation component in bowel-preparation products, but it is not merely an inactive excipient in those products.

Can PEG 3350 be sold as an OTC monograph product?

Yes. A PEG 3350 laxative can be marketed under the applicable FDA OTC laxative requirements when the formulation, labeling and claims comply with the relevant monograph conditions [1].

Are PEG 3350 laxative products protected by Orange Book patents?

Ordinary OTC monograph PEG 3350 powders generally do not depend on Orange Book patent protection. Prescription PEG-electrolyte products and other approved drug products require separate Orange Book and patent analysis.

What excipient best differentiates a PEG 3350 powder?

No single excipient provides a universal advantage. Flavor systems, sweeteners, flow aids and moisture-control packaging can create differentiation, but commercial value depends on measurable improvements in dissolution, palatability, stability or convenience.

Is a flavored PEG 3350 product commercially attractive?

Yes, if the flavor improves adherence without creating excessive sweetness, sediment, odor or stability problems. A flavored product is more defensible when combined with unit-dose packaging, low-sugar positioning or a defined pediatric or travel-use strategy.

References

1. U.S. Food and Drug Administration. (2024). Laxative drug products for over-the-counter human use, 21 C.F.R. Part 334; OTC Monograph M007.
2. National Library of Medicine. (2024). DailyMed: Polyethylene glycol 3350 powder for solution product labeling.
3. U.S. Food and Drug Administration. (2024). Approved drug products and labeling for polyethylene glycol-electrolyte solutions.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.